Number of the records: 1

Perspective of Use of Antiviral Peptides against Influenza Virus

SYSNO ASEP	0457799
Document Type	J - Journal Article
R&D Document Type	Journal Article
Subsidiary J	Článek ve WOS
Title	Perspective of Use of Antiviral Peptides against Influenza Virus
Author(s)	Skaličková, S. (CZ) Heger, Z. (CZ) Krejčová, L. (CZ) Pekárik, V. (CZ) Bastl, K. (CZ) Janda, Jozef (UZFG-Y)_RID Kostolanský, F. (SK) Varečková, E. (SK) Zítka, O. (CZ) Adam, V. (CZ) Kizek, R. (CZ)
Source Title	Viruses. - : MDPI Roč. 7, č. 10 (2015), s. 5428-5442
Number of pages	15 s.
Publication form	Print - P
Language	eng - English
Country	CH - Switzerland
Keywords	cationic peptides ; hemagglutinin ; influenza virus
Subject RIV	EE - Microbiology, Virology
R&D Projects	ED2.1.00/03.0124 GA MŠMT - Ministry of Education, Youth and Sports (MEYS)
Institutional support	UZFG-Y - RVO:67985904
UT WOS	000364242200017
EID SCOPUS	84944901079
DOI	10.3390/v7102883
Annotation	The threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20(th) century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides.
Workplace	Institute of Animal Physiology and Genetics
Contact	Jana Zásmětová, knihovna@iapg.cas.cz, Tel.: 315 639 554
Year of Publishing	2016

Number of the records: 1